CANNABINOID 1 RECEPTOR BLOCKADE DIMINISHES OBESITY AND DYSLIPIDEMIA VIA PERIPHERAL ACTIVATION OF BROWN ADIPOSE TISSUE

The endocannabinoid system is an important player in energy metabolism by regu-lating appetite, lipolysis and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintained weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not been clarified yet. In this study, we show that systemic CB1R blockade by rimonabant in a diet-induced obese mouse model for human-like lipoprotein metabolism reversed obesity, increased energy expenditure and lowered plasma VLDL-triglycerides (TG). Mechanistic studies showed that rimonabant selectively increased VLDL-TG clearance by brown adipose tissue (BAT) accompanied by decreased lipid droplet size in BAT. Of note, the mechanism involved peripheral activation of BAT since the effects were still present at thermoneutral temperature at which sympathetic output towards BAT is negligible and could be fully recapitulated by using the strictly peripheral CB1R antagonist AM6545. In support, we demonstrate that the CB1R is highly expressed in BAT and that in vitro blockade of the CB1R in cultured brown adipocytes increased UCP-1 content and lipolysis. Our data indicate that selective targeting of the peripheral CB1R in BAT has therapeutic potential in attenuating dyslipidemia and obesity.

[1]  W. D. van Marken Lichtenbelt,et al.  Brown adipose tissue volume in healthy lean south Asian adults compared with white Caucasians: a prospective, case-controlled observational study. , 2014, The lancet. Diabetes & endocrinology.

[2]  F. Villarroya,et al.  BMP8B Increases Brown Adipose Tissue Thermogenesis through Both Central and Peripheral Actions , 2012, Cell.

[3]  L. Havekes,et al.  Estimation of Activity Related Energy Expenditure and Resting Metabolic Rate in Freely Moving Mice from Indirect Calorimetry Data , 2012, PloS one.

[4]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[5]  A. Efeyan,et al.  Pten positively regulates brown adipose function, energy expenditure, and longevity. , 2012, Cell metabolism.

[6]  Sang Geon Kim,et al.  Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gαi/o Inhibition , 2011, Molecular Pharmacology.

[7]  T. Hankemeier,et al.  Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice , 2011, PloS one.

[8]  Oliver T. Bruns,et al.  Brown adipose tissue activity controls triglyceride clearance , 2011, Nature Medicine.

[9]  R. Zimmermann,et al.  Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. , 2010, European journal of pharmacology.

[10]  S. Ambudkar,et al.  Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. , 2010, The Journal of clinical investigation.

[11]  J. Orava,et al.  Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.

[12]  W. D. van Marken Lichtenbelt,et al.  Cold-activated brown adipose tissue in healthy men. , 2009, The New England journal of medicine.

[13]  E. Palmer,et al.  Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.

[14]  N. Tennagels,et al.  Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle , 2009, Diabetologia.

[15]  B. Oldfield,et al.  The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure , 2009, Obesity.

[16]  C. Kahn,et al.  New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure , 2008, Nature.

[17]  G. Marsicano,et al.  Cannabinoid Type 1 Receptor Blockade Promotes Mitochondrial Biogenesis Through Endothelial Nitric Oxide Synthase Expression in White Adipocytes , 2008, Diabetes.

[18]  J. Jukema,et al.  Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. , 2008, Atherosclerosis.

[19]  P. Soubrié,et al.  Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats , 2007, Hepatology.

[20]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[21]  J. Jukema,et al.  Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[23]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[24]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[25]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[26]  P. Soubrié,et al.  The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[28]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[29]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[30]  L. Petrocellis,et al.  The endocannabinoid system: a general view and latest additions , 2004, British journal of pharmacology.

[31]  D. Piomelli The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[32]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[33]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[35]  T. V. van Berkel,et al.  Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. , 2001, Journal of lipid research.

[36]  F. Walker,et al.  Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. , 1998, The Journal of clinical investigation.

[37]  J. K. Kruijt,et al.  Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B , 1995, Nature Medicine.

[38]  J. Brunzell,et al.  Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. , 1993, Journal of lipid research.

[39]  I. Feurer,et al.  Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry , 1986 .

[40]  C. E. West,et al.  Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.

[41]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[42]  Sandra M. Sanabria-Bohórquez,et al.  The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. , 2008, Cell metabolism.